Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
You may also be interested in...
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.